Cite
HARVARD Citation
Hagins, D. et al. (2018). Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials1. HIV medicine. 19 (10), pp. 724-733. [Online].